

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/193745 A1

- (51) **International Patent Classification:**
C07K 16/08 (2006.01) *A61P 31/20* (2006.01)
- (21) **International Application Number:**
PCT/EP2020/058681
- (22) **International Filing Date:**
27 March 2020 (27.03.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1904328.0 28 March 2019 (28.03.2019) GB
- (71) **Applicant: IMMUNOCORE LIMITED** [GB/GB]; 101 Park Drive Milton Park, Abingdon Oxfordshire OX14 4RY (GB).
- (72) **Inventors: CONNOLLY, Mary Marguerita;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). **TORREÑO, Sara Crespillo;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). **SUCK-LING, Richard;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). **DEMBEK, Marcin;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB).

(GB). **DONOSO, Jose;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). **WIEDERHOLD, Katrin;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). **KNOX, Andrew;** c/o Immunocore Limited 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB).

(74) **Agent: KILBURN & STRODE LLP;** Lacon London 84 Theobalds Road, London WC1X 8NL (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) **Title: BINDING MOLECULES SPECIFIC FOR HBV ENVELOPE PROTEIN**

Figure 1

SEQ ID NO: 2 Amino acid sequence of the scaffold alpha chain extracellular region. CDRs are underlined. The extracellular constant region is shown in italics. A non-native cysteine residue is shown in bold (at position 48 of constant region)

```
10      20      30      40      50      60
AKSVKQNSGP LSVPEGALAS LNCYYSURGE QSYYWYSCYS GKSPLLIMSL YENGQALDGR
70      80      90      100     *10     120
FTAQINRASQ YVSLLRDSQ PDSACYLCA VRHYTDRLI EGTGCRQVE FNIQNTDPAV
130     140     150     160     *70     180
YQLRDSKSSD KYCLFTDFD SQTWVSQSKD SDVYITKCV LNRSHDFKS NSAVANGNKS
190
DPAQMAFNN STIPEDT
```

SEQ ID NO: 3 Amino acid sequence of the scaffold beta chain extracellular region. CDRs are underlined. The extracellular constant region is shown in italics. A non-native cysteine residue is shown in bold (at position 57 of constant region). Additional non-native amino acids at position 75 and position 89 of the constant region are also shown in bold.

```
10      20      30      40      50      60
NAGVTQPRF QVLKTCQSHF LQCAQDMHHS YMSWYRQDQG HCLRLIHYSV CAGITDQGEV
70      80      90      100     *10     120
PHGYNVSRT TEDFPLRLLS AAFQCCSYVF CASSTATGGT GLEFFGEGSS LTVLEPLKAV
130     140     150     160     170     180
FFPEYAVFEP SEALSHITQK ATLVLATGE YFDIVELSNM VNGKEVHISGV CTDFQPLKEQ
190     200     210     220     230     240
PALNDSRYAL SSRLVVSATF WQDPRNHPRC QVQFVGLSEN DEWTQDRANK VTQIVSAEZW
GRAD
```

(57) **Abstract:** The present invention relates to specific binding molecules that bind the HLA-A*02 restricted peptide GLSPTVWLSV (SEQ ID NO: 1) derived from HBV envelope protein. The specific binding molecules may comprise alpha and/or beta TCR variable domains and may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious or malignant disease.

WO 2020/193745 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*